Pan-genomic Testing for Cancer
(INTERCEPTioN Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial aims to uncover genetic causes and markers of cancer by analyzing participants' DNA and other biological samples. Researchers hope to discover better ways to prevent, diagnose, and treat cancer through these studies. The trial includes two groups: one will undergo both germline (inherited) and somatic (tumor) testing, while the other will have only germline testing. People with a confirmed cancer diagnosis who can provide a sample, such as blood or saliva, might be a good fit for this trial. As an unphased trial, this study offers participants the chance to contribute to groundbreaking research that could lead to significant advancements in cancer care.
Do I need to stop my current medications for the trial?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
What prior data suggests that pan-genomic testing is safe for cancer patients?
Research has shown that pan-genomic testing, which examines both inherited and acquired genetic changes, is generally easy for participants to handle. In past studies, the process of collecting and analyzing DNA succeeded in about 80% to 90% of cases, indicating reliability for most people. One study found that identifying genetic changes, a part of this testing, was extremely accurate and consistent, with no false positives and a 99.7% repeatability rate.
The testing itself usually causes no harmful effects, as it primarily involves examining genetic material from samples like blood or tissue. The goal is to identify genetic changes that could aid in understanding or treating cancer. This type of testing is already widely used in cancer research and treatment, indicating its safety for participants.12345Why are researchers excited about this trial?
Researchers are excited about the INTERogating Cancer protocol because it focuses on using genetic testing to tailor cancer treatment options. Unlike standard treatments that often follow a one-size-fits-all approach, this trial utilizes germline and somatic testing to understand the genetic makeup of both the patient and the cancer itself. This personalized approach has the potential to identify more effective and targeted therapies for individuals, potentially improving outcomes and reducing unnecessary side effects. By delving into the genetic roots of cancer, the trial could pave the way for more precise and effective treatment strategies in the future.
What evidence suggests that this trial's pan-genomic testing could be effective for cancer?
This trial will compare two approaches to pan-genomic testing for cancer patients. Group A will undergo both germline and somatic testing, while Group B will receive germline testing only. Studies have shown that pan-genomic testing, which examines both inherited and acquired DNA changes, can be very helpful for cancer patients. In a large study with over 11,000 patients, about 17% had an important inherited genetic change that affected their cancer. Testing for acquired DNA changes has also guided treatment decisions, especially in breast cancer, where it helps determine if chemotherapy is needed. Another study successfully sequenced DNA in 80%–90% of samples, demonstrating the process's reliability for most patients. These findings suggest that pan-genomic testing can provide valuable insights into cancer, potentially leading to better prevention, earlier diagnosis, and more effective treatment options.16789
Who Is on the Research Team?
Jewel J. Samadder, M.D.
Principal Investigator
Mayo Clinic
Are You a Good Fit for This Trial?
Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Genomic Sequencing
Genomic sequencing of tumor tissue and blood to determine genomic alterations in cancer-related genes
Biobanking
Creation of a biobank of samples and information to learn more about treating cancer
Follow-up
Participants are monitored for safety and effectiveness after genomic sequencing
What Are the Treatments Tested in This Trial?
Interventions
- Pan-genomic Testing
How Is the Trial Designed?
2
Treatment groups
Experimental Treatment
Potential participants with a cancer diagnosis may be identified through the following sources: patients who will undergo or are currently undergoing clinical evaluation in practices such as, but not limited to, hematology-oncology, gastroenterology-hepatology, radiation-oncology and surgery. Participants will be enrolled in the study indefinitely unless a request to withdraw is made.
Potential participants with a cancer diagnosis may be identified through the following sources: patients who will undergo or are currently undergoing clinical evaluation in practices such as, but not limited to, hematology-oncology, gastroenterology-hepatology, radiation-oncology and surgery. Participants will be enrolled in the study indefinitely unless a request to withdraw is made.
Find a Clinic Near You
Who Is Running the Clinical Trial?
Mayo Clinic
Lead Sponsor
Citations
Utility of Germline, Somatic and ctDNA Testing in Adults With ...
DNA extraction and genomic/panel sequencing were successful for approximately 80%–90% of samples, regardless of whether the sample was fresh‐ ...
Universal Germline and Tumor Genomic Testing Needed ...
In a pan-cancer study (>50 cancer types) of 11,947 patients, 17% (n = 2,037) harbored a germline likely pathogenic or pathogenic variant; 9% (n ...
Detecting likely germline variants during tumor-based ...
In the largest pan-cancer study of its kind, Tung et al. examined comprehensive genomic profiling data in over 125,000 patients with advanced ...
Clinical Impact of Somatic Genomic Testing on Breast ...
Somatic genomic tests are now used routinely to inform decisions regarding adjuvant chemotherapy use in selected early breast cancer patients.
Precision proteogenomics reveals pan-cancer impact of ...
We investigate the impact of germline variants on cancer patients' proteomes, encompassing 1,064 individuals across 10 cancer types.
Somatic Genomic Testing in Patients With Metastatic or ...
Genomic testing should also be performed in patients with metastatic or advanced solid tumors if there are clearly defined resistance markers for a treatment ...
Precise identification of somatic and germline variants in the ...
Reference sample analysis revealed a 0% false positive rate and 99.7% reproducibility for variant calling. Assessing 2864 tumor samples across ...
The Future of Parallel Tumor and Germline Genetic Testing
Under the traditional paradigm of genetic testing in cancer, the role of germline testing was to assess for the inherited risk of cancer, whereas the role ...
9.
genomemedicine.biomedcentral.com
genomemedicine.biomedcentral.com/articles/10.1186/s13073-025-01429-5TP53 germline testing and hereditary cancer: how somatic ...
The study comprises a total of 6161 unrelated patients suspected of having a hereditary cancer syndrome based on young/early age at cancer ...
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.